• KOL
    • Hydatidiform Mole
    • Shoshichi Takeuchi
    • Shoshichi Takeuchi: Influence Statistics

      Shoshichi Takeuchi

      Shoshichi Takeuchi

      National Defense Medcl Coll, Tokorozawa, Saitama, Japan; Tohoku Univ, Sch of Medicine, Sendai, Japan; Aichi Cancer Ctr Hosp, Nagoya, Japan; Osaka City Gen Hosp, Osaka, Japan; ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Shoshichi Takeuchi:Expert Impact

      Concepts for whichShoshichi Takeuchihas direct influence:Hydatidiform mole,Radiation therapy,Cervical cancer,Uterine cervical cancer,Nude mice,Placental proteins,Trophoblastic disease,Invasive mole.

      Shoshichi Takeuchi:KOL impact

      Concepts related to the work of other authors for whichfor which Shoshichi Takeuchi has influence:Cervical cancer,Uterine cervix,Hydatidiform mole,Neoadjuvant chemotherapy,Irinotecan hydrochloride,Spontaneous abortion,Radiation therapy.

      KOL Resume for Shoshichi Takeuchi

      Year
      2005

      National Defense Medcl Coll, Tokorozawa, Saitama, Japan; Tohoku Univ, Sch of Medicine, Sendai, Japan; Aichi Cancer Ctr Hosp, Nagoya, Japan; Osaka City Gen Hosp, Osaka, Japan; Jichi Medcl Coll, Tochigi, Japan; Tottori Univ, Sch of Medicine, Yonago, Japan; Kobe National Hosp, Kobe, Japan; Iwate Medcl Coll, Morioka, Japan

      2002

      Departments of Obstetrics and Gynecology, Kurume University, Kurume;, Kinki University, Osakasayama;, Wakayama Medical School, Wakayama;, Hyogo Medical Center for Adults, Akashi;, Asahikawa Medical College, Asahikawa;, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka;, Shikoku National Cancer Center, Matsuyama;, Niigata Prefectural Cancer Center, Niigata;, Tohoku University, Sendai;, Jikei Medical University, Tokyo;, Nagoya University, Nagoya;, Kita-tama Hospital, and, Department of Epidemiology and Biostatistics, School of Health Sciences and Nursing, Tokyo University, Tokyo, Japan

      2000

      Departments of Obstetrics and Gynecology, Kurume University, Kurume, Kinki University, Osaka, Sapporo Medical University, Sapporo, Tohoku University, Sendai, Nagoya University, Nagoya, Jikei University, Tokyo, Kita-tama Hospital, Tokyo, National Shikoku Cancer Center, Matsuyama, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Niigata Cancer Center, Niigata, Osaka City University, Osaka, Kagoshima City Hospital, Kagoshima, Department of Epidemiology and Biostatistics, School of Health Sciences and Nursing, Tokyo University, Tokyo, Japan

      1996

      Biotechnology Research Center, Teikyo University, 907 Nogawa, Miyamae-ku, Kawasaki, 216, Kanagawa, Japan

      1993

      Clinical Division, Biotechnology Research Center, Teikyo University, Kanagawa

      1991

      Dept. of Obstetrics and Gynecology, Niigata University, School of Medicine.

      1990

      The Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo Japan

      1989

      Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata City, Asahimachi‐Dori, 1‐757, Japan

      1988

      Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata, Japan.

      1987

      Department of Obstetrics and Gynecology, School of Medicine, Niigata University, Asahi-Machi-Dori-1-757, Niigata City, Japan

      1986

      Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigala, Japan Address correspondence and reprint requests to Dr. M. Sasagawa, at Department of Obstetrics and Gynecology, Niigata University School of Medicine. 1–757 Asahimachi Dori, Niigata, 951 Japan.

      1985

      Department of Obstetrics and Gynecology, School of Medicine, Niigata University, I Asahimachi‐Dori, Niigata, Japan

      1984

      Department of Obstetrics and Gynecology, School of Medicine Niigata University, Niigata, Japan

      1983

      Department of Obstetrics and Gynecology, Niigata University School of Medicine, Japan

      1982

      Department of Obstetrics and Gynecology; Niigata University, Asahimachi, Niigata, Japan

      1981

      Department of Obstetrics and Gynecology, Niigata University, School of Medicine, Niigata

      1971

      Department of Obstetrics and Gynaecology School of Medicine Niigata University Niigata, Japan

      1969

      Virology Division, National Cancer Center Research Institute, Tsukiji 5‐chome, Chuo‐ku, Tokyo and Department of Obstetrics and Gynecology, School of Medicine, University of Tokyo, Bunkyo‐ku, Tokyo, Japan

      Sample of concepts for which Shoshichi Takeuchi is among the top experts in the world.
      Concept World rank
      trophoblastic embolism #2

      Prominent publications by Shoshichi Takeuchi

      KOL-Index: 12673

      Irinotecan (CPT-11) and cisplatin are singly active against cervical cancer. We evaluated the efficacy and toxicity of CPT-11 plus cisplatin as first-line chemotherapy in patients with advanced or recurrent cervical cancer. Twenty-nine chemotherapy-naive patients with advanced or recurrent cervical cancer were treated with CPT-11 (60 mg/m(2)) on days 1, 8, and 15 by intravenous infusion over 90 min, followed by cisplatin (60 mg/m(2) i.v.) on day 1 over 90 min. The patients' median age ...

      Known for Cervical Cancer | Irinotecan Cisplatin | 3 Patients | Recurrent Disease | Cpt11 60
      KOL-Index: 9391

      To elucidate an immunological mechanism in terms of the effectiveness of vaccination of the unexplained habitual aborters with their husband's lymphocytes, 20 patients were selected as the experimental group, and 10 fertile couples were selected as the control group. Subjects were studied by mixed lymphocyte reaction-blocking assay so as to determine whether they had blocking antibodies (BAbs) in their sera. In the experimental group, BAb levels were found to be significantly lower as ...

      Known for Successful Pregnancy | Unexplained Recurrent Aborters | Husbands Lymphocytes | Blocking Antibodies | Immunological Mechanism
      KOL-Index: 8808

      Tumor-specific antibodies reacted with an isografted ascitic form of mouse mammary tumor, MM2, with a higher sensitivity in an immune adherence test than in an immune cytotoxicity test. Immune adherence and immune adherence inhibition tests were applied for the detection of surface antigens of MM2 tumor reacting with tumor-specific antibodies. After treatment with ether, ethanol, methanol, ethanol-ether mixture, acetone, chloroform-methanol mixture, deoxycholate, triton × 100, snake ...

      Known for Immune Adherence | Surface Antigens | Immunological Studies | Mammary Tumor | Mm2 Cells
      KOL-Index: 8130

      Immunohistochemical localization of HLA antigens and placental proteins (alpha hCG, beta hCG CTP, hPL and SP1) in villous and extravillous trophoblast at various stages of normal human gestation were studied, using hysterectomy specimens. In the chorionic villi, the capacity for synthesizing placental proteins seemed to develop in parallel with the morphological change from mononuclear cells to multinucleated syncytiotrophoblast and no villous trophoblast expressed HLA antigens. In ...

      Known for Extravillous Trophoblast | Beta Subunit | Normal Human | Chorionic Villi | Pregnancy Proteins
      KOL-Index: 7458

      OBJECTIVE: To evaluate the efficacy and toxicity of a combination of irinotecan (CPT-11) and cisplatin as first-line chemotherapy in advanced ovarian cancer.

      METHODS: Twenty-six patients with previously untreated advanced epithelial ovarian cancer were enrolled in this study. CPT-11 60 mg/m(2) was administered intravenously on days 1, 8, and 15 in combination with cisplatin 60 mg/m(2) on day 1. Cycles were repeated every 28 days for at least two cycles. The median patient age was 55 ...

      Known for Ovarian Cancer | Combination Cisplatin | Firstline Chemotherapy | 1 8 | Humans Irinotecan
      KOL-Index: 7436

      After injection of isografted mammary tumor MM2 sensitized with rabbit antiserum, resistance was induced in C3H/He mice after repeated challenges with MM2. The serum taken from these mice was found to be cytotoxic against MM2 cells. The serum also inhibited the outgrowth of transplant of primary tissue culture cells of spontaneous mammary tumor of C3H/He mice. A series of transplanted mammary tumors recently converted into ascitic form in our laboratory (MM3, MM4-1, MM4-2, MM4-3, MM6, ...

      Known for Mammary Tumors | Immunological Studies | C3h Mice | Mm2 Cells | Tumor‐specific Antibodies
      KOL-Index: 7364

      Thirty-nine unexplained recurrent aborters underwent vaccination using husband's lymphocytes according to the previously reported protocol. No mixed lymphocyte culture reaction-blocking antibodies (MLR-BAbs) were observed in these patients prior to vaccination. Of 35 newly pregnant patients after vaccination(s), pregnancy successfully continued in 28 (80.0%) and have already been terminated with a liveborn offspring. Pregnancy outcome was also analyzed in unexplained recurrent aborters ...

      Known for Unexplained Recurrent | Immunotherapy Patients | Blocking Antibodies | Habitual Adult | Husbands Lymphocytes
      KOL-Index: 7118

      To evaluate the clinical effects of the anti-tumor polysaccharide Schizophyllan (SPG), a randomized study was done on 220 patients with Stage II or Stage III cervical cancer who had been given irradiation, concomitantly. The tumor-reducing effect of SPG was significant in patients in either stage. The time to recurrence was longer in SPG-dosed patients with Stage II cancer, compared with findings in the control group. There was no significant difference in the time to recurrence in ...

      Known for Cervical Cancer | Clinical Evaluation | Spg Patients | Difference Time | Randomized Controlled Study
      KOL-Index: 6872

      BACKGROUND: The failure rate with radiation therapy alone for Stage III cervical cancer is quite high, and therefore other modalities are being pursued as adjuvants to radiation therapy in hopes of improving the results.

      METHODS: A randomized, controlled, comparative study on the efficacy and safety of radiation therapy combined with LC9018 (a biologic response modifier prepared from heat-killed Lactobacillus casei YIT9018) was conducted using 228 patients with Stage IIIB cervical ...

      Known for Radiation Therapy | Prolonged Survival | Lactobacillus Casei | Uterine Cervical | Randomized Controlled
      KOL-Index: 6577

      An isografted tumor MM2, originating from a spontaneous mammary tumor in a C3H/He/mouse, killed 4- to 5-week-old mice within 30 days through intraperitoneal injection of 2 × 104 cells per mouse. It was shown that resistance to the isograft was induced by injection of 1.5 × 105 or 2.0 × 105 tumor cells sensitized with serum (5 μg antibody N) of rabbits immunized with the tumor. Four weeks after injection of the sensitized MM2 cells, 173 C3H/He mice were challenged intraperitoneally with ...

      Known for Immunological Studies | Mammary Tumor | C3h Mice | Intraperitoneal Injection | Mm2 Cells
      KOL-Index: 5419

      Abstract Lipopolysaccharide (LPS) has been recognized as a potent antitumor agent in animal tumor models; however, its use in human cancer therapy has been limited to only one trial, in which LPS from Salmonella was given intravenously. It was not very successful because of poor tumor response and was also toxic. We originally developed LPS prepared from Pantoea agglomerans (LPSp), and this was a well-purified, small-molecular-mass (5 kDa) agent. We chose intradermal rather than ...

      Known for Intradermal Administration | Lpsp Treatment | Pantoea Agglomerans | Tumor Regression | Lipopolysaccharide Lps
      KOL-Index: 5257

      A high incidence of autoimmune oophoritis can be induced in (C57BL/6Cr x A/J)F1 mice that were thymectomized at 3 days of age. The vaginal opening day was significantly delayed (thymectomized mice [n = 35], 38.1 +/- 5.8 days [mean +/- SD] versus sham thymectomized mice [n = 26], 34.0 +/- 5.2 days; p less than 0.02). Most of the thymectomized mice showed irregular estrous cycles during the first several weeks and then fell into continuous diestrus. Local infiltration of mononuclear and ...

      Known for Autoimmune Oophoritis | Premature Ovarian Failure | 3 Age | Zona Pellucida | Mice Thymectomized
      KOL-Index: 4917

      Antigens present in mouse mammary tumor MM2 reacting with tumor-specific antibodies were extracted with 0.2% deoxycholate. After the removal of deoxycholate by dialysis, most antigens were precipitated by centrifugation at 105,000 × g for 60 min. Hyperimmunization of C3H/He mice with these antigens induced heightened resistance against MM2. Antibodies appeared in the serum after a booster injection of deoxycholate extract of tumor cells was given. Antigens were solubilized from ...

      Known for Mammary Tumor | Immunological Studies | C3h Mice | Heightened Resistance | Antigen Antibody
      KOL-Index: 4617

      The authors studied data of combination assays of tumor markers, because simultaneous elevation of different types of tumor markers in the serum was puzzling. They interpreted such phenomena regarding cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors. The tissue expression of the antigens was compared with preoperative serum levels. Several different factors were found to cause the simultaneous elevation of two or three of these markers in ...

      Known for Ovarian Tumors | Carcinoembryonic Antigen | Tumor Markers | Tissue Expression | Preoperative Serum Levels

      Key People For Hydatidiform Mole

      Top KOLs in the world
      #1
      Ross Stuart Berkowitz
      ovarian cancer molar pregnancy gestational trophoblastic
      #2
      Donald Peter Goldstein
      molar pregnancy gestational trophoblastic hydatidiform mole
      #3
      Rosemary Ann Fisher
      hydatidiform mole molar pregnancies gestational trophoblastic
      #4
      Michael J Seckl
      gestational trophoblastic hydatidiform mole molar pregnancy
      #5
      Kenneth D Bagshawe
      germ cell hydatidiform mole human chorionic gonadotrophin
      #6
      Neil James Sebire
      hydatidiform mole wilms tumor twin pregnancies

      National Defense Medcl Coll, Tokorozawa, Saitama, Japan; Tohoku Univ, Sch of Medicine, Sendai, Japan; Aichi Cancer Ctr Hosp, Nagoya, Japan; Osaka City Gen Hosp, Osaka, Japan; Jichi Medcl Coll, Tochigi, Japan; Tottori Univ, Sch of Medicine, Yonago, Ja

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.